MARKHAM, ON, April 17, 2013 /CNW/ - Genitourinary cancer research in Canada will receive additional funding thanks to a new research collaboration between the Canadian Urologic Oncology Group (CUOG) and Astellas Pharma Canada, Inc. (Astellas).
This year, Astellas has pledged $50,000 to further Canadian investigators' peer-reviewed research into finding medicines and cures for urological disorders, focusing specifically on prostate cancer.
The CUOG/Astellas Research Awards in prostate cancer will range between $10,000 and $25,000 each, depending on the number of applicants received, and are in addition to Astellas' multi-year commitment to the Canadian urology community through the CUA Astellas Research Grant program.
"For over 20 years, the Canadian Urologic Oncology Group has promoted research by students, residents and fellows through annual CUOG awards. Under the supervision of CUOG members, students have conducted research that has led to some extremely valuable findings and, in many cases, served as the foundation for larger projects and research careers," says Dr. Fred Saad, Chair of the National Cancer Institute of Canada G-U Group and the Canadian Urologic Oncology Group. "We are very pleased to be able to increase the amount of money available for CUOG awards due to additional funding provided by Astellas Pharma Canada."
Urology continues to be a priority therapeutic area for Astellas and the company is proud to support the efforts of the Canadian urology community through its ongoing contributions to investigator research and patient programs.
"Innovations that result from discovery research can potentially have a great impact on patients in the future," says Michael Tremblay, President, Astellas Pharma Canada. "We are honoured to contribute to advancing uro-oncology research, with the hope that one day it will produce a cure for genitourinary cancers."
Applications for the CUOG/Astellas Research Awards are due May 1, 2013 and the recipients will be announced at the annual CUOG meeting on June 22.
For more information, please visit CUOG's website, www.cuog.org.
About the Canadian Urologic Oncology Group (CUOG)
The Canadian Urologic Oncology Group (CUOG) is a clinical research investigator network of leading academic and community based urologists, medical oncologists, and radiation oncologists, committed to furthering genitourinary (GU) cancer research in Canada.
CUOG pursues clinical trials in concert with the pharmaceutical industry to find medicines and cures to tackle urological disorders including, but not restricted to:
- Prostate cancer
- Bladder cancer
- Renal cancer
- Testicular cancer
More information about CUOG can be found at www.cuog.org.
About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.
The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. In Canada, Astellas has an intense commercial focus on five therapeutic areas - Urology, Immunology, Infectious Disease, Dermatology and Oncology.
For more information about Astellas Pharma Canada, Inc., please visit the corporate website: www.astellas.ca
SOURCE: Astellas Pharma Canada, Inc.
Naomi Côté
Corporate Communications
Astellas Pharma Canada, Inc.
(905) 946-5621
[email protected]
Share this article